Cytotoxic T lymphocyte-associated molecule-4 gene polymorphism and hyperthyroid Graves' disease relapse after antithyroid drug withdrawal: A follow-up study

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 7, 2007, Pages 2513-2518

  Wang, Pei Wen ^a   Chen, I Ya ^a   Liu, Rue Tsuan ^a   Hsieh, Ching Jung ^a   Hsi, Edward ^b,c   Juo, Suh Hang Hank ^b,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; THYROTROPIN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; EXON; FEMALE; FOLLOW UP; GENETIC MODEL; GENOTYPE; GOITER; GRAVES DISEASE; HAPLOTYPE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 34447118880     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2761     Document Type: Article

References (28)

1. Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S, Cassell D, Brunner M, Allison JP 1996 The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev 153:27-46
2. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH 1995 Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547
3. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA 1994 CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405-413
4. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo Jr VA, Ke X, Gray GS, Nadler LM 1995 CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 92:811-815
5. Awata T, Kurihara S, Iitaka M, Takei S, Inoue I, Ishii C, Negishi K, Izumida T, Yoshida Y, Hagura R, Kuzuya N, Kanazawa Y, Katayama S 1998 Association of CTLA-4 gene A-G polymorphism (IDDM12 locus) with acute-onset and insulin-depleted IDDM as well as autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in the Japanese population. Diabetes 47:128-129
6. Chistyakov DA, Savost'anov KV, Turakulov RI, Petunina NA, Trukhina LV, Kudinova AV, Balabolkin MI, Nosikov VV 2000 Complex association analysis of Graves disease using a set of polymorphic markers. Mol Genet Metab 70:214-218
7. Heward JM, Allahabadia A, Armitage M, Hattersley A, Dodson PM, Macleod K, Carr-Smith J, Daykin J, Daly A, Sheppard MC, Holder RL, Barnett AH, Franklyn JA, Gough SC 1999 The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab 84:2398-2401
8. Park YJ, Chung HK, Park DJ, Kim WB, Kim SW, Koh JJ, Cho BY 2000 Polymorphism in the promoter and exon 1 of the cytotoxic T lymphocyte antigen-4 gene associated with autoimmune thyroid disease in Koreans. Thyroid 10:453-459
9. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ 1995 CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 80:41-45
10. Yung E, Cheng PS, Fok TF, Wong GW 2002 CTLA-4 gene A-G polymorphism and childhood Graves' disease. Clin Endocrinol (Oxf) 56:649-653
11. Wang PW, Liu RT, Juo SH, Wang ST, Hu YH, Hsieh CJ, Chen MH, Chen IY, Wu CL 2004 Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves' hyperthyroidism after antithyroid withdrawal. J Clin Endocrinol Metab 89:169-173
12. Kroczek R, Hamelmann E 2005 T-cell costimulatory molecules: optimal targets for the treatment of allergic airway disease with monoclonal antibodies. J Allergy Clin Immunol 116:906-909
13. Kotsa K, Watson PF, Weetman AP 1997 A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin Endocrinol (Oxf) 46:551-554
14. Ban Y, Davies TF, Greenberg DA, Kissin A, Marder B, Murphy B, Concepcion ES, Villanueva RB, Barbesino G, Ling V, Tomer Y 2003 Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immun 4:586-593
15. Furugaki K, Shirasawa S, Ishikawa N, Ito K, Ito K, Kubota S, Kuma K, Tamai H, Akamizu T, Hiratani H, Tanaka M, Sasazuki T 2004 Association of the T-cell regulatory gene CTLA4 with Graves' disease and autoimmune thyroid disease in the Japanese. J Hum Genet 49:166-168
16. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ronningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC 2003 Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511
17. Weng YC, Wu MJ, Lin WS 2005 CT60 single nucleotide polymorphism of the CTLA-4 gene is associated with susceptibility to Graves' disease in the Taiwanese population. Ann Clin Lab Sci 35:259-264
18. Barrett JC, Fry B, Maller J, Daly MJ 2005 Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
19. Tzeng JY, Wang CH, Kao JT, Hsiao CK 2006 Regression-based association analysis with clustered haplotypes through use of genotypes. Am J Hum Genet 78:231-242
20. Cordell HJ, Clayton DG 2002 A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. Am J Hum Genet 70:124-141
21. Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J 2001 CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2:145-152
22. Sahin M, Erdogan MF, Erdogan G 2005 Cytotoxic T lymphocyte-associated molecule-4 polymorphisms in Turkish Graves' disease patients and association with probability of remission after antithyroid therapy. Eur J Intern Med 16:352-355
23. Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K, Hackenberg K, Dettmann J, Prehn B, Hirche H, Mann K 2002 Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid 12:1119-1128
24. Wallaschofski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R 2002 Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment. Horm Metab Res 34:383-388
25. Ahmed S, Ihara K, Kanemitsu S, Nakashima H, Otsuka T, Tsuzaka K, Takeuchi T, Hara T 2001 Association of CTLA-4 but not CD28 gene polymorphisms with systemic lupus erythematosus in the Japanese population. Rheumatology (Oxford) 40:662-667
26. Machida H, Tsukamoto K, Wen CY, Narumi Y, Shikuwa S, Isomoto H, Takeshima F, Mizuta Y, Niikawa N, Murata I, Kohno S 2005 Association of polymorphic alleles of CTLA4 with inflammatory bowel disease in the Japanese. World J Gastroenterol 11:4188-4193
27. Rodriguez MR, Nunez-Roldan A, Aguilar F, Valenzuela A, Garcia A, Gonzalez-Escribano MF 2002 Association of the CTLA4 3′ untranslated region polymorphism with the susceptibility to rheumatoid arthritis. Hum Immunol 63:76-81
28. Wang XB, Kakoulidou M, Giscombe R, Qiu Q, Huang D, Pirskanen R, Lefvert AK 2002 Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 130:224-232